Clinical study of azithromycin on patients with idiopathic pulmonary fibrosis
10.3760/cma.j.issn.1673-4904.2011.25.001
- VernacularTitle:阿奇霉素对特发性肺纤维化患者的临床研究
- Author:
Bin LIU
;
Lili ZHU
;
Wei ZHANG
- Publication Type:Journal Article
- Keywords:
Pulmonary fibrosis;
Treatment outcome;
Azithromycin
- From:
Chinese Journal of Postgraduates of Medicine
2011;34(25):1-3
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo estimate the effect of azithromycin on lung function and transforming growth factor β1(TGF- β1) in patients with idiopathic pulmonary fibrosis (IPF). MethodsOne hundred and ten patients with IPF were divided into two groups by random digits table. Patients in azithromycin group(60cases) were treated by azithromycin tablets and thoee in placebo group ( 50 cases) were treated by placebo tablets, and they were observed for 12 weeks. Lung function was detected at beginning and after 6,12 weeks' treatment. TGF- β1 was tested by ELISA, meanwhile patient's condition was observed. ResultsAfter 6 and 12 weeks' treatment, the forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), carbonmonoxide diffusion capacity (DLCO) in the two groups had no significant differences compared with those at beginning of treatment (P ＞ 0.05). After 12 weeks' treatment, the level of TGF- β1 in azithromycin group was significantly decreased compared with that at beginning and after 6 weeks' treatment (P ＜ 0.05) ,but there was no significant difference in placebo group (P ＞ 0.05). The ratio of acute exacerbation admission and infection was 8.3％(5/60) and 60.0％(3/5) in azithromycin group, 22.0％( 11/50) and 81.8％(9/11 ) in placebo group,and there were significant differences between the two groups(P ＜0.05 or ＜0.01). Conclusion Azithromycin may reduce the ratio of acute exacerbation admission and infection, decrease TGF- β 1 expression in patients with IPF by taking orally for a long time, but it may have no obvious effect on lung function.
